PMID: 42169198

Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.

Al-Jarshawi Mustafa, Cole Andrew, Bagur Rodrigo, Wang Hao-Yu, Ng Cheng Han, Yu Dahai, Chew Nicholas W S, Mamas Mamas A

Cardiovascular diabetology. Endocrinology reports · 2026

Vol. 12, Issue 1

View on PubMedDOI

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.